Background Chronic heart failure (CHF) remains an important cause of morbidity and mortality worldwide. Currently, there are no cost-effectiveness studies of eplerenone use in patients with New York Heart Association (NYHA) class II CHF. Objective We sought to evaluate the cost effectiveness of eplerenone compared with placebo in patients with chronic systolic heart failure and NYHA class II symptoms. Methods and results A 10-year Markov model with yearly cycles was constructed to evaluate the cost effectiveness of eplerenone compared with placebo, based on data from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) study. The model classified subjects into two health states: 'Alive with CHF' and 'Dead'. Information about the cost of disease was derived from Australian Refined DiagnosisRelated Groups (AR-DRG) data. The cost of eplerenone was taken from the Australian Pharmaceutical Benefit Scheme. Utility data were derived from published sources, and a 5 % annual discount rate was applied to future costs and benefits. Over 10 years, and compared with placebo, the model predicted that eplerenone would lead to a saving of 0.5 life-years (discounted) and 0.4 quality-adjusted lifeyears (QALYs) per person. The net cost was (in Australian dollars [$A]) $A6,117 (discounted) per person. These equated to incremental cost-effectiveness ratios of $A12,024 per life-year saved and $A16,700 per QALY saved. Sensitivity analyses indicated that these results were robust. Conclusion Eplerenone may represent a cost-effective strategy for preventing morbidity and mortality among patients with chronic systolic heart failure and NYHA class II symptoms.
CHF in this setting is 1-2 % [3] [4] [5] [6] , and the estimated incidence is 5-10 per 1,000 individuals per year [7] . There were over 45,000 hospital separations for heart failure in Australia in 2009-2010 [7] . In financial terms, heart failure is estimated to account for 2.5 % of national healthcare budgets, with hospital costs accounting for up to 70 % of total costs [8] .
Current Australian treatment guidelines [4] for management of patients with CHF and New York Heart Association (NYHA) class II symptoms recommend the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers and beta-blockers (unless contraindicated). Diuretics are used to relieve symptoms and aid with maintenance of euvolaemia. Based on the findings of the recently published EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) trial, the guidelines now recommend consideration of an aldosterone receptor antagonist such as eplerenone [4, 9] .
The EMPHASIS-HF trial assigned 2,737 patients with systolic (left ventricular ejection fraction [LVEF] B30 %) CHF and NYHA class II symptoms to receive eplerenone (up to 50 mg daily) or placebo in addition to standard care [9] . The primary outcome was a composite of death from cardiovascular causes and hospitalization for heart failure. After a median follow-up period of 21 months, the primary outcome occurred in 18.3 % of patients in the eplerenone group compared with 25.9 % in the placebo group (hazard ratio [HR] 0.63, 95 % confidence interval [CI] 0.54-0.74, p \ 0.001). Death occurred in 12.5 % of the eplerenone group compared with 15.5 % of the placebo group (HR 0.76, 95 % CI 0.62-0.93, p = 0.008). Deaths due to cardiovascular causes occurred in 10.8 and 13.5 %, respectively (HR 0.76, 95 % CI 0.61-0.94, p = 0.01), while hospitalizations due to heart failure occurred in 12.0 and 18.4 %, respectively (HR 0.58, 95 % CI 0.47-0.70, p \ 0.001) [9] .
Currently, there are no published cost-effectiveness studies of eplerenone use in CHF patients with NYHA class II from an Australian healthcare perspective. In the present study, we sought to determine the cost effectiveness of eplerenone compared with placebo in patients with chronic systolic heart failure (LVEF B35 %) and NYHA class II symptoms. The modelled economic evaluation extrapolated key efficacy data from the EMPHASIS-HF study.
Methods

Model
We created a decision-analytic state transition Markov model [10] with 1-year cycles to compare the health and economic effects of eplerenone compared with placebo (in addition to standard therapy) for patients with systolic CHF and NYHA class II symptoms. The model comprised only two health states: 'Alive with CHF' and 'Dead' (Fig. 1) .
All subjects entered the model in the 'Alive with CHF' health state and progressed through four possible transition states: (i) 'No heart failure hospitalization, stay alive'; (ii) 'Heart failure hospitalization, stay alive' (hospitalization comprised an overnight stay or longer in a hospital environment with a discharge diagnosis that included a cardiovascular reason); (iii) 'cardiovascular death', (due to heart failure, myocardial infarction, cardiac arrhythmia, stroke, or other cardiovascular cause) regardless of what other non-fatal events may have occurred in that cycle prior to death; and (iv) 'Non-cardiovascular death', regardless of what other non-fatal events may have occurred in that cycle prior to death.
The transition state 'Heart failure hospitalization, stay alive' defined the occurrence of any number of heart failure hospitalizations (C1) and survival (no death) until the end of the cycle. Deaths occurring within any cycle were assumed to be mutually exclusive to non-fatal heart failure hospitalizations (and any other events).
The economic evaluation was undertaken from the perspective of the Australian healthcare system using Australian dollars ($A), year 2013 values. The cost effectiveness of eplerenone versus placebo was expressed as incremental cost-effectiveness ratios (ICER) in terms of $A per years of life saved (YoLS) and $A per quality-adjusted life-year (QALY) gained. In the base-case analysis, the time horizon of the model was 10 years.
Model Population
The model population comprised an arbitrary 1,000 subjects, who were profiled based on the study population of the EMPHASIS-HF study. EMPHASIS-HF was a randomized, double-blind, clinical trial. The eplerenone arm comprised 1,364 patients and the placebo arm 1,373. The key baseline characteristics of subjects in EMPHASIS-HF are summarized in Table 1 . In brief, the key inclusion criteria for EMPHASIS-HF were age C55 years; NYHA class II symptoms; LVEF B30 % (or if [30 and B35 %, QRS duration on electrocardiogram [ECG] of [130 ms); treatment with an ACEI, angiotensin receptor blocker or both; and treatment with a beta-blocker [9] (unless contraindicated) ( Table 1) .
At baseline in the EMPHASIS-HF study, medication use was similar between the two groups due to randomization. Subsequent changes in medication use were not described in the study. Therefore, in our analysis, we assumed that, other than eplerenone, medication use did not differ between the two groups over the entire time horizon. This assumption was conservative (disfavored eplerenone) because in practice, eplerenone would likely decrease the need for other heart failure medications and hence decrease associated costs.
The transition probabilities for the placebo group underpinning transitions in cycle 1 were derived directly from the placebo arm of the EMPHASIS-HF study ( Table 2 ). The transition probabilities for cycles 2 and beyond were extrapolated from those in cycle 1 via application of expected age-related trends. Age-related trends were extracted from life tabling of 2007 mortality data provided in the Australian Institute of Health and Welfare's (AIHW) General Record of Incidence of Mortality (GRIM) [11] (Appendix). At the start of cycle 1 in the model, subjects were assumed to be aged 68 years, as this was the mean age of EMPHASIS-HF subjects at baseline.
For cycle 2, the transition probabilities for heart failure hospitalizations and cardiovascular death were increased over those for cycle 1 by the same proportion as observed for deaths from circulatory causes when moving from age 68 years to age 69 years. The transition probability for non-cardiovascular death was increased over that for cycle 2 by the same proportion as observed for deaths from noncirculatory causes when moving from age 68 years to age 69 years. This process was then repeated for all subsequent cycles.
Transition probabilities for subjects in the eplerenone group were derived by applying HRs for eplerenone versus placebo to the transition probabilities in the placebo group. These HRs were those derived from analysis of complete double-blinded data by Zannad et al. [9] . The key HRs were as follows: 0.60 (95 % CI 0.49-0.72) for heart failure hospitalizations, 0.79 (95 % CI 0.65-0.96) for cardiovascular death, and 0.77 (95 % CI 0.64-0.92) for all-cause mortality [9] .We assumed that the HR for non-cardiovascular mortality would be the same as that for all-cause mortality.
The model did not specify the progression of subjects into NYHA class III and IV symptom categories, nor their regression to the NYHA class I category. Rather, the living health state assumed that all subjects remained in the NYHA class II category (with relevant utilities and costs applied-see below). In reality, CHF severity can regress and progress over time, and therefore, in cycles 2 and beyond, there would be a mix of subjects in the various NYHA classes. Our model did not distinguish living subjects according to NYHA class as there were no data to allow estimation of the transition probabilities to underpin movement among the NYHA classes.
Utilities
Utility values used in the model were relevant to subjects residing in the health state 'Alive with CHF (NYHA II)'. The model applied the utility of 0.72 (95 % CI 0.69-0.75), as reported in the Australian study by Ford et al. [12] . The utilities used from Ford et al. were derived from Yao et al. [13] from 768 patients in the CARE-HF (Cardiac Resynchronization -Heart Failure) study in NYHA class III and IV.
Costs
The cost of a heart failure hospitalization and cardiovascular death was derived from the latest available data from Australian Refined Diagnosis-Related Groups (AR-DRGs) (2009-2010) [14, 15] . The weighted-average cost of a heart failure hospitalization and a hospitalized cardiovascular death were updated to 2013 values using the total health price index published by the AIHW [16] . The costs were $A6,872 and $A3,507, respectively. We only assigned the cost of a single heart failure hospitalization to subjects who made this transition, despite that more than one hospitalization may have occurred. Furthermore, costs of heart failure hospitalization were not assigned to subjects who died in a cycle, despite that this may have preceded the death. Lastly, an assumption was made that only 50 % of all cardiovascular deaths would be hospitalized, and thus the unit cost of a cardiovascular death was $A1,754. This figure was also assumed to be the cost of a non-cardiovascular death. The significant heterogeneity of non-cardiovascular causes of death meant that it was not feasible to estimate a cost from AR-DRG data. Background costs of treating patients with NYHA class II CHF (excluding hospitalizations) were estimated from Ford et al. [12] and updated to 2013 values. The annual background costs were $A175, and applied to all years lived by subjects in the model. The cost of eplerenone was derived from the Australian Pharmaceutical Benefits Scheme (PBS) [17] , which already funds eplerenone for Australian patients post-myocardial infarction. Each of the 25-mg and 50-mg doses was $A3.76 per day, equating to an annual cost of $A1,374. Ancillary costs associated with monitoring for urea and electrolytes (item number 66512) were derived from the Australian Medical Benefit Schedule (MBS) [12] . We assumed that patients would have monthly tests for urea and electrolytes in the first 3 months of eplerenone therapy, followed by 3-monthly testing thereafter. The total cost of monitoring was therefore $A71.20 in the first year, and $A35.60 in subsequent years [18] .
Discounting
In the base-case analysis, discounting at a rate of 5 % [19] per annum was applied to costs, years of life, and QALYs lived.
Sensitivity Analyses
One-way sensitivity analyses were undertaken with variation to key data inputs. The values of these key input parameters were altered one at a time, while maintaining all other inputs at base-case values. A probabilistic sensitivity analysis was also performed via Monte Carlo simulation with 5,000 iterations. Variables that were included in the Monte Carlo simulation [20, 21] were utilities (using Beta distributions), costs (using Uniform distributions), and transition probabilities (using Triangular distributions). Costs of treatment and those associated with monitoring of eplerenone were considered to have fixed values. Information about input variables and their uncertainty distributions are summarized in Table 2 .
We used Microsoft Ò Excel (Microsoft Corporation, Redmond, WA, USA) and @risk (Palisade Corporation, Ithaca, NY, USA) to implement the model, and TreeAge Annual pharmaceutical costs 1,374
CHF chronic heart failure, CI confidence interval, CV cardiovascular, HF heart failure, NYHA New York Heart Association, PSA probabilistic sensitivity analyses, $A Australian dollar Pro 2011(TreeAge software Inc, Williamstown, MA, USA) for flow diagrams.
Results
In the base-case analysis, among a cohort of 1,000 patients with CHF and NYHA class II symptoms, the model predicted that the placebo group would experience 697 heart failure hospitalizations, 791 cardiovascular deaths, and 97 non-cardiovascular deaths over a 10-year period. The eplerenone group would experience 488 heart failure hospitalizations, 731 cardiovascular deaths, and 86 noncardiovascular deaths. The differences equated to numbers needed to treat (NNT) over 10 years of 5, 17, and 90 for heart failure hospitalizations, cardiovascular deaths, and non-cardiovascular deaths, respectively. Over the 10-year period, subjects in the placebo group were predicted to live an average of 4.6 years and 3.3 QALYs (discounted), and incurred a net cost of $A6,010 (discounted) per person. Subjects in the eplerenone group lived an average of 5.1 years and 3.7 QALYs (discounted), and incurred a net cost of $A12,127 per person (discounted). Thus the ICERs for eplerenone versus placebo over 10 years were $A12,024 per YoLS and $A16,700 per QALY saved.
Sensitivity Analyses
The results of one-way sensitivity analyses (Tables 3, 4) showed that results were most sensitive to efficacy measures (especially regarding cardiovascular mortality) and the price of eplerenone. The results of probabilistic sensitivity analyses are summarized as a cost-effectiveness acceptability curve in Fig. 2 , with 95 % uncertainty intervals of $A8,570-27,239 per YoLS, and $A11,880-38,108 per QALY saved. At a willingness-to-pay threshold of B$A45,000 per YoLS, there would be a 99.0 % probability that eplerenone would be cost effective. At a willingnessto-pay threshold of B$A45,000 per QALY gained, there would be a 99.0 % probability that eplerenone would be cost effective.
Discussion
Based on our modelling analysis, eplerenone is likely to represent cost-effective treatment of Australian patients with CHF and NYHA class II symptoms. A willingness-topay threshold of below $A45,000 per YoLS and QALY for Australia correspond to a probability of being cost effective, as recommended by the PBS [22] .
The univariate sensitivity analyses showed that the ICERs were highly sensitive to efficacy measures (cardiovascular mortality) from EMPHASIS-HF and the price of eplerenone. For example, when the upper limit of the 95 % CI, for the HR associated with cardiovascular mortality (0.97) from EMPHASIS-HF was applied, eplerenone was no longer cost effective.
To our knowledge, there have hitherto been no published cost-effectiveness analyses of eplerenone specifically for CHF NYHA class II. Other studies have assessed the cost effectiveness of eplerenone in a post-myocardial infarction setting [23] [24] [25] [26] [27] [28] [29] [30] . These suggested that eplerenone would be cost effective compared with either spironolactone [26] or placebo [23] [24] [25] [27] [28] [29] .
Our results are subject to several limitations. First, we adopted disease and mortality risks directly from the EMPHASIS study. Clinical trial populations are seldom representative of 'real-life' clinical populations (the former are usually selected for higher risk of the primary outcomes) and clinical trial conditions may differ from those of the real world [31] . This assumption was made given the absence of robust epidemiological data on CHF in Australia to allow for determination of underlying risks of hospitalizations and death [12, 32] . However, a halving of the underlying risks of hospitalization and death were tested in sensitivity analyses and the conclusion remained unchanged. Furthermore, the median duration of the EMPHASIS-HF study was 21 months, as compared with the 10-year time horizon of the model. We assumed, as clinical practice does in the setting of long-term preventive therapy, that the benefit of eplerenone would be preserved as long as patients continued to receive it. Full compliance with treatment was also assumed in the model. This is of course ambitious [33, 34] , but in reality would make little difference to the modelled cost-effectiveness of eplerenone. The reason is that while benefits would be reduced with less compliance, so too would costs in roughly proportional terms.
Another limitation is that we did not specify the progression of subjects into NYHA class III and IV symptom categories, or their regression to the NYHA class I category. As mentioned, this assumption was made, as there were no data to allow estimation of the relevant transition probabilities underpinning movement among NYHA classes. The assumption was conservative in terms of the cost effectiveness of eplerenone because eplerenone is likely to result in improved symptom status and hence retarded progression to class III and IV CHF. However, this would have been offset by the fact that patients with class III and IV CHF may have been treated with spironolactone. In the absence of head-to-head studies of eplerenone and spironolactone, and indeed even placebo-controlled studies of eplerenone in class III and IV CHF and placebo-controlled studies of spironolactone in class II CHF, the relative efficacy of eplerenone versus spironolactone in the clinical setting is not known. Nevertheless, because spironolactone is considerably cheaper ($A0.12 for a 25-mg daily dose via the PBS) than eplerenone, its 'cost-efficacy ratio' is likely to be high.
An obvious limitation to our analysis is that it adopted the perspective of the Australian healthcare system, which is universal in its coverage and predominantly publicly funded. Hence all disease and intervention costs were those of the Australian healthcare system. Utility data were also drawn from an Australian study. However, all other inputs were not Australian-specific, key among which were those pertaining to underlying disease and death risks and the efficacy of eplerenone (both sourced from the EMPHASIS-HF study). Therefore, our model could easily be applied to another country, with only substitution of that country's specific cost and utility inputs. Finally, the model was conservative in its approach by not assigning long-term disutilities and costs to subjects who experienced heart failure hospitalizations. This assumption was made as there were no specific data to inform costs and utilities pre and post-heart failure hospitalization. Our study also underestimated the number of incident heart failure cases by not counting those that preceded death in a cycle. These would likely have served to underestimate the true cost effectiveness of eplerenone.
Conclusion
Eplerenone is likely to represent a highly effective and costeffective means of preventing heart failure hospitalizations CHF chronic heart failure, CI confidence interval, CV cardiovascular, HF heart failure, ICER incremental cost-effectiveness ratio, LL lower limit, QALY quality-adjusted life-year, UL upper limit, YoLS year of life saved Costs are expressed in Australian dollars, and all future costs and outcomes are discounted at 5 % annually CI confidence interval, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, UI uncertainty intervals (95 % CI), YoLS years of life saved a Including costs associated with monitoring and deaths among Australian patients with chronic systolic heart failure and NYHA class II symptoms. In general in Australia, an intervention associated with an incremental cost-effectiveness ratio between $A15,000 and $A45,000 per life-year and quality-adjusted life-year gained is considered cost effective [22] . QALY quality-adjusted life-year, YoLS year of life saved, $A Australian dollar 
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